{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:51Z","timestamp":1793781891968,"version":"4.6.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the management of Crohn\u2019s disease [CD] in Phase 3 clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Our goal was to describe our real-world experience with upadacitinib in CD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a two-centre retrospective cohort study of adult patients with moderate to severe CD on upadacitinib. The primary outcome was clinical response and remission as determined by stool frequency and abdominal pain scores. Secondary endpoints included endoscopic response and remission as determined by change in Simple Endoscopic Score for CD. Outcomes were assessed at 3 months after starting upadacitinib and at the patient\u2019s most recent follow-up. We further evaluated adverse events and dose-related response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 45 CD patients received upadacitinib and were included in the safety analysis. Thirty-six patients received upadacitinib for CD, whereas nine received it for inflammatory arthritis [n\u2005=\u20058] or pyoderma [n\u2005=\u20051]. Thirty-three patients received upadacitinib for 3 months or longer and were included in the efficacy analysis. At the 3-month follow-up, 21 patients achieved clinical response [63.6%] and nine achieved clinical remission [27.2%]. At time of last follow-up, 23 patients had clinical response [69.7%], ten achieved clinical remission [30.3%] and four [28.6%] achieved endoscopic remission. Adverse events occurred in 12 patients [26.7%]. Two patients had a serious adverse event [4.5%] without associated mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this real-world cohort of highly refractory CD patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjac157","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T15:57:16Z","timestamp":1666454236000},"page":"504-512","source":"Crossref","is-referenced-by-count":35,"title":["Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn\u2019s Disease"],"prefix":"10.1093","volume":"17","author":[{"given":"Rishika","family":"Chugh","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of California San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-1753","authenticated-orcid":false,"given":"Manuel B","family":"Braga-Neto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-1574","authenticated-orcid":false,"given":"Thomas W","family":"Fredrick","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme P","family":"Ramos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Terdiman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of California San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"El-Nachef","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of California San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-6851","authenticated-orcid":false,"given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-8061","authenticated-orcid":false,"given":"Uma","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of California San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6410-4242","authenticated-orcid":false,"given":"Sunanda V","family":"Kane","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"2023041916523118300_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2023041916523118300_CIT0002","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"2023041916523118300_CIT0003","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet."},{"key":"2023041916523118300_CIT0004","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet."},{"key":"2023041916523118300_CIT0005","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2023041916523118300_CIT0006","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2023041916523118300_CIT0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2023041916523118300_CIT0008","doi-asserted-by":"crossref","first-page":"i036","DOI":"10.1093\/ecco-jcc\/jjab232.032","article-title":"OP33 Effect of upadacitinib [UPA] treatment on extraintestinal manifestations [EIMs] in patients with moderate-to-severe ulcerative colitis [UC]: results from the UPA Phase 3 programme","volume":"16","author":"Colombel","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023041916523118300_CIT0009","doi-asserted-by":"crossref","first-page":"S021","DOI":"10.1093\/ecco-jcc\/jjab075.022","article-title":"OP23 Efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023041916523118300_CIT0010","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","article-title":"A review of upadacitinib in rheumatoid arthritis","volume":"30","author":"Tanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023041916523118300_CIT0011","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","article-title":"Efficacy of JAK inhibitors in Crohn\u2019s disease","volume":"14","author":"Rogler","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023041916523118300_CIT0012","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/ibd\/izab116","article-title":"Randomized controlled trial substudy of cell-specific mechanisms of janus kinase 1 inhibition with upadacitinib in the Crohn\u2019s disease intestinal mucosa: analysis from the CELEST study","volume":"27","author":"Aguilar","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2023041916523118300_CIT0013","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2023041916523118300_CIT0014","volume-title":"Upadacitinib (RINVOQ\u00ae) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn\u2019s Disease","year":"2021"},{"key":"2023041916523118300_CIT0015","volume-title":"Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ\u00ae) Improved Clinical and Endoscopic Outcomes in Patients with Crohn\u2019s Disease","year":"2022"},{"key":"2023041916523118300_CIT0016","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2023041916523118300_CIT0017","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2023041916523118300_CIT0018","article-title":"Induction efficacy of upadacitinib in therapy-refractory Crohn\u2019s disease: a retrospective case series","author":"Pokryszka","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023041916523118300_CIT0019","article-title":"Upadacitinib is safe and effective for Crohn\u2019s disease: real-world data from a tertiary center","author":"Traboulsi","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2023041916523118300_CIT0020","first-page":"304","article-title":"Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn\u2019s disease","volume":"26","author":"Lewis","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2023041916523118300_CIT0021","doi-asserted-by":"crossref","first-page":"2065383","DOI":"10.1155\/2020\/2065383","article-title":"Correlation of Patient-Reported Outcome (PRO-2) with endoscopic and histological features in ulcerative colitis and Crohn\u2019s disease patients","volume":"2020","author":"Dragasevic","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"2023041916523118300_CIT0022","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","article-title":"Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2023041916523118300_CIT0023","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ajg.2016.177","article-title":"Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn\u2019s disease","volume":"111","author":"Deepak","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2023041916523118300_CIT0024","article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study","author":"D\u2019Haens","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023041916523118300_CIT0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2023041916523118300_CIT0026","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjac157\/47486909\/jjac157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/4\/504\/50033605\/jjac157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/4\/504\/50033605\/jjac157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T16:55:04Z","timestamp":1681923304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/4\/504\/6770027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,22]]},"published-print":{"date-parts":[[2023,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac157","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,10,22]]}}}